Tu1472 Multimodal Assessment of Gastric Residence Time, Whole Bowel Transit, Esophageal Function and Gastro-Esophageal Reflux Following Administration of the Motilin Agonist (GSK962040) in Healthy Subjects

Hobson, Anthony; Dewit, Odile; O'Donnell, M.; Hacquoil, Kimberley; Mahmoud, Yasmin; Robertson, Darren; Dukes, George E.

doi:10.1016/s0016-5085(12)63266-1

Gastroenterology

2012

DOI: 10.1016/s0016-5085(12)63266-1

|View full text |Cite

Tu1472 Multimodal Assessment of Gastric Residence Time, Whole Bowel Transit, Esophageal Function and Gastro-Esophageal Reflux Following Administration of the Motilin Agonist (GSK962040) in Healthy Subjects

Anthony Hobson¹,

Odile Dewit²,

M. O'Donnell³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2014

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

The investigational drug camicinal for the treatment of gastroparesis

Barshop

Kuo

2014

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

Introduction: Gastroparesis is a syndrome of delayed gastric emptying in the absence of mechanical obstruction that presents with upper gastrointestinal symptoms. Despite its growing prevalence, there remains an unmet clinical need for more efficacious prokinetic treatment options. The current market includes prokinetic agents that reduce gastroparesis symptoms. However, adverse drug effects and tachyphylaxis with repeated dosing are among the factors that limit their use. Camicinal (GSK962040) is the most advanced, small-molecule, selective motilin receptor agonist with therapeutic potential to date. Areas covered: This article reviews the literature on the limitations of current prokinetic agents used in the treatment of gastroparesis. It also summarizes the current evidence and influential clinical trial results involving the investigational drug camicinal, and shares its preliminary findings from the literature. Expert opinion: Camicinal represents a new opportunity as a treatment in a clinical area in need of new agents. There is emerging literature to support how the drug addresses both gastroparesis symptoms and dysmotility with no significant adverse effects or tachyphylaxis reported to date. Challenges remain in getting a new compound approved for gastroparesis. However, careful design of future trials will help to continue the record of success camicinal trials have had thus far.

show abstract

The investigational drug camicinal for the treatment of gastroparesis

Barshop

Kuo

2014

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Tu1472 Multimodal Assessment of Gastric Residence Time, Whole Bowel Transit, Esophageal Function and Gastro-Esophageal Reflux Following Administration of the Motilin Agonist (GSK962040) in Healthy Subjects

Cited by 1 publication

References 0 publications

The investigational drug camicinal for the treatment of gastroparesis

The investigational drug camicinal for the treatment of gastroparesis

Contact Info

Product

Resources

About